Back to the list
Congress: ECR25
Poster Number: C-25335
Type: Poster: EPOS Radiologist (scientific)
DOI: 10.26044/ecr2025/C-25335
Authorblock: I. N. Yucel, T. Orhan, A. Görmez, G. Beydagi, N. Alan Selcuk, O. M. Topcuoğlu; Istanbul/TR
Disclosures:
Ismail Necim Yucel: Nothing to disclose
Tolga Orhan: Nothing to disclose
Ayşegül Görmez: Nothing to disclose
Gamze Beydagi: Nothing to disclose
Nalan Alan Selcuk: Nothing to disclose
Osman Melih Topcuoğlu: Nothing to disclose
Keywords: Molecular imaging, PET-CT, Diagnostic procedure, Neoplasia
References
  1. Sollini M, Kirienko M, Gelardi F, Fiz F, Gozzi N, Chiti A. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48 :4396-4414. doi: 10.1007/s00259-021-05475-0.
  2. Zhao L, Chen J, Pang Y,  et al. Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review. Theranostics. 2022 Jan 9;12:1557-1569. doi: 10.7150/thno.69475.
  3. Sharma P, Singh SS, Gayana S. Fibroblast Activation Protein Inhibitor PET/CT: A Promising Molecular Imaging Tool. Clin Nucl Med. 2021;1;46:e141-e150. doi: 10.1097/RLU.0000000000003489.
  4. Levy MT, McCaughan GW, Marinos G, Gorrell MD. Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver. 2002;22:93-101. doi: 10.1034/j.1600-0676.2002.01503.x.
  5. Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, Yin R. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;28;12:86. doi: 10.1186/s13045-019-0770-1.
  6. Sandberg TP, Stuart MPME, Oosting J, et al. Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer. BMC Cancer. 2019;29;19:284. doi: 10.1186/s12885-019-5462-2.
  7. Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60:801-805. doi:10.2967/jnumed.119.227967.
  8. Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18:99-115. doi: 10.1038/s41573-018-0004-1.
  9. Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39:783-803. doi: 10.1007/s10555-020-09909-3.
  10. Loktev A, Lindner T, Mier W, et al. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J Nucl Med. 2018;59:1423-1429. doi: 10.2967/jnumed.118.210435.
  11. Chen H, Pang Y, Wu J, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47:1820-1832. 
  12. Ruan D, Zhao L, Cai J, Xu W, Sun L, Li J, et al. Evaluation of FAPI PET imaging in gastric cancer: a systematic review and meta-analysis. Theranostics. 2023;13:4694-4710.
  13. Lin R, Lin Z, Chen Z, Zheng S, Zhang J, Zang J, et al. [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2022;49:2960-2971.
  14. Fu L, Huang S, Wu H, Dong Y, Xie F, Wu R, et al. Superiority of [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT to [18F]FDG PET/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer. Eur Radiol. 2022;32:6281-6290.
  15. Wang Y, Luo W, Li Y. [68Ga]Ga-FAPI-04 PET MRI/CT in the evaluation of gastric carcinomas compared with [18F]-FDG PET MRI/CT: a meta-analysis. Eur J Med Res. 2023;28:34.
  16. Singh SB, Shrestha BB, Gandhi OH, Shah RP, Mukhtiar V, Ayubcha C, et al. The comparative utility of FAPI-based PET radiotracers over [18F]FDG in the assessment of malignancies. Am J Nucl Med Mol Imaging. 2024;14:190-207.
  17. Wang T, Huang G, Zhao H, Li L, Shen Y, Lou W, et al. [68Ga]Ga-FAPI-04 PET/MR imaging strategy in management of Krukenberg tumors (KTs) from gastric signet-ring-cell carcinoma: to overcome limitation of [68Ga]Ga-FAPI-04 PET imaging in KTs. Eur J Nucl Med Mol Imaging. 2024;51:3440-3449.
  18. Li X, Lv X, Quan Z, Han T, Tang Y, Liu Y, et al. Surgical evidence-based comparison of [68Ga]Ga-FAPI-04 PET and MRI-DWI for assisting debulking surgery in ovarian cancer patients. Eur J Nucl Med Mol Imaging. 2024;51:1773-1785.
  19. Lin Y, Gao H, Zheng J, Al-Ibraheem A, Hu P, Shi H. Clinical Explorations of [68Ga] Ga-FAPI-04 and [18F] FDG Dual-Tracer Total-body PET/CT and PET/MR Imaging. Semin Nucl Med. 2024;54:904-913.
  20. Roth KS, Voltin CA, van Heek L, Wegen S, Schomäcker K, Fischer T, et al. Dual-Tracer PET/CT Protocol with [18F]-FDG and [68Ga]Ga-FAPI-46 for Cancer Imaging: A Proof of Concept. J Nucl Med. 2022;63:1683-1686.
  21. Liu G, Mao W, Yu H, Hu Y, Gu J, Shi H. One-stop [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study. Eur J Nucl Med Mol Imaging. 2023;50:2271-2281
GALLERY